-
Signature
-
/s/ Jonathan Wygant, as attorney-in-fact
-
Issuer symbol
-
VCYT
-
Transactions as of
-
02 Mar 2026
-
Net transactions value
-
-$485,429
-
Form type
-
4
-
Filing time
-
04 Mar 2026, 16:16:46 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Febbo Phillip G. |
Chief Scientific & Med Officer |
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO |
/s/ Jonathan Wygant, as attorney-in-fact |
04 Mar 2026 |
0001649245 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
VCYT |
Common Stock |
Tax liability |
|
-6,035 |
-4.4% |
$36.01* |
130,771 |
02 Mar 2026 |
Direct |
F1 |
| transaction |
VCYT |
Common Stock |
Sale |
$485,429 |
-13,425 |
-10% |
$36.16 |
117,346 |
02 Mar 2026 |
Direct |
F2, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: